CN1883619A - Pharmaceutical composition of viola yedoensis and method for preparing same - Google Patents
Pharmaceutical composition of viola yedoensis and method for preparing same Download PDFInfo
- Publication number
- CN1883619A CN1883619A CN 200610035666 CN200610035666A CN1883619A CN 1883619 A CN1883619 A CN 1883619A CN 200610035666 CN200610035666 CN 200610035666 CN 200610035666 A CN200610035666 A CN 200610035666A CN 1883619 A CN1883619 A CN 1883619A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- viola yedoensis
- ultrafiltration
- preparation
- viola
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention pharmaceutical composition containing Viola philippica Cav. polysaccharides, which is prepared from Viola philippica Cav. through extracting and purifying. The invention also provides the process for preparing the pharmaceutical composition and its use in pharmaceutical production. The pharmaceutical composition has good effect for suppressing viruses, especially for suppressing hepatitis B viruses and HIV viruses.
Description
Technical field:
The present invention relates to a kind of medicinal effective site of Herba Violae, particularly a kind of pharmaceutical composition that contains highly purified viola yedoensis and preparation method thereof.
Background technology:
Herba Violae is the dry herb of Violaceae Chinese violet Viola yedoensis Makino.Spring, Qiu Erji gather, and remove impurity, dry.Bitter in the mouth, suffering, cold in nature.GUIXIN, Liver Channel.Heat-clearing and toxic substances removing, the removing heat from blood detumescence.Herb contains the esters of polysaccharide, saponin, flavonoid, wax, cerinic acid and unsaturated acids.Modern study shows that the polysaccharide component of Herba Violae has the effect that suppresses HIV (human immunodeficiency virus) on cell culture medium, and its polysaccharide component can strengthen body immunity simultaneously.But prior art is not illustrated the effective site of viola yedoensis onset, in using, field of medicaments do not carry out deep research and evaluation, but also fail to provide the preparation method of the pharmaceutical composition of viola yedoensis of industrialization, this has all had a strong impact on the application of Herba Violae in medicine.
As everyone knows, hepatitis B and acquired immune deficiency syndrome (AIDS) equally all are the diseases that threatens human health or even life, and being used for antiviral drug at present is not that DeGrain is exactly that medical expense is too high, is not suitable for China's national situation.This just requires us to develop determined curative effect, antiviral drugs with low cost, the Chinese medicine culture is of extensive knowledge and profound scholarship, the herbal species of heat-clearing and toxic substances removing is numerous, and therefrom the specific medicament of exploitation treatment difficult miscellaneous diseases, severe crisis is an important directions of China's modernization of Chinese medicine.The Herba Violae tradition just is used for heat-clearing and toxic substances removing, we extract the polysaccharide effective site that is purified into Herba Violae by a large amount of experiments, and find its multiple medical usage unexpectedly, this is not that those of ordinary skill just can not realized by performing creative labour, more be not conspicuous, the successful development and application of this pharmaceutical composition is significant.
Summary of the invention:
One of purpose of the present invention provides a kind of pharmaceutical composition of viola yedoensis, and another object of the present invention provides a kind of preparation method of pharmaceutical composition of viola yedoensis.
In order to achieve the above object, the present invention has taked following technological means:
We provide a kind of pharmaceutical composition of viola yedoensis, are made through extracting purification by Herba Violae, and wherein polysaccharide component accounts for more than 50% of solid content.
It is better that experiment discovery polysaccharide component is not less than 80% o'clock effect.
Discover that further the main onset composition of viola yedoensis is that mean molecule quantity is 11000 ± 2000 polysaccharide component, wherein the polysaccharide component of molecular weight 5000-20000 is not less than 80%.We use the high-performance liquid chromatogram determination said composition, and a topmost polysaccharide chromatographic peak is arranged in the GPC gel chromatography, and mean molecule quantity is between 11000 ± 2000.
By further purification, the pharmaceutical composition of viola yedoensis polyoses content can reach more than 90%.
Between this polysaccharide mean molecule quantity 11000 ± 2000 of GPC chromatographic determination, molecular weight distribution 1.10-1.20, Mz/Mw 1.20-1.30.
We provide the preparation method of this pharmaceutical composition of viola yedoensis, may further comprise the steps:
1) the Herba Violae medical material obtains crude polysaccharides with the mode of conventional water extraction reuse ethanol precipitation, and perhaps elder generation obtains crude polysaccharides with the mode of organic solvent degreasing reuse water extraction;
2) aqueous solution of crude polysaccharides is crossed the ultrafiltration post of the molecular weight 20,000-200,000 that dams, and collects ultrafiltrate;
3) ultrafiltrate is collected the ultrafiltration mother solution after the ultrafiltration post of molecular weight less than 5000 that dam, and the concentrated after drying of ultrafiltration mother solution that the 3rd step collected promptly gets pharmaceutical composition of viola yedoensis.
50,000 or 100,000 ultrafiltration post is preferably used in ultrafiltration for the first time.More preferably 50,000 ultrafiltration post.
5000 or 3000 ultrafiltration post is preferably used in ultrafiltration for the second time.
In order to obtain the better viola yedoensis compositions of purity, we can adopt ultrafiltrate after the ultrafiltration for the first time to cross the method for macroporous adsorbent resin, remove hydrophobicity impurity.
The resin that uses comprises D101, D380, D280, ADS-7, ADS-8, HPD-300 or SA-1 model.The preferred strong polar macroporous adsorption resin of resin comprises ADS-7 or SA-1 resin.
The viola yedoensis of our preparation can be realized by following step:
1) the Herba Violae medical material obtains crude polysaccharides with the mode of conventional water extraction reuse ethanol precipitation, and perhaps elder generation obtains crude polysaccharides with the mode of organic solvent degreasing reuse water extraction;
2) crude polysaccharides solution is crossed 50,000 ultrafiltration post, collects ultrafiltrate;
3) ultrafiltrate is crossed the SA-1 resin, collects effluent and water lotion and merges;
4) the 3rd step gained solution is crossed 5000 ultrafiltration post, the ultrafiltration mother solution, the ultrafiltration mother solution dry pharmaceutical composition of viola yedoensis.
The viola yedoensis of our narration also can be realized by following step:
1) the Herba Violae medical material obtains crude polysaccharides with the mode of conventional water extraction reuse ethanol precipitation, and perhaps elder generation obtains crude polysaccharides with the mode of organic solvent degreasing reuse water extraction;
2) crude polysaccharides solution is crossed 50,000 ultrafiltration post, collects ultrafiltrate;
3) ultrafiltrate is crossed the ADS-7 resin, collects effluent and water lotion and merges;
4) the 3rd step gained solution is crossed 5000 ultrafiltration post, the ultrafiltration mother solution, the ultrafiltration mother solution dry pharmaceutical composition of viola yedoensis.
We also provide the application of pharmaceutical composition of viola yedoensis in preparation anti-virus aspect medicine, comprise hepatitis B virus or HIV (human immunodeficiency virus).
We also provide the application of pharmaceutical composition of viola yedoensis in preparation enhance immunity medicine.
We also provide the application of pharmaceutical composition of viola yedoensis in preparation used as adjuvant drug for antitumor thing.
The extraction of success of the present invention has filtered out the effective ingredient of Herba Violae, and further purification has been carried out in this active ingredient, has obtained pharmaceutical composition of viola yedoensis.By a large amount of experiment sievings, provide this preparation of drug combination method.The evidence of vitro inhibition virus, pharmaceutical composition of the present invention have virus and suppress effect, especially hepatitis B virus and HIV virus have been duplicated the good restraining function.By pharmacological testing, prove that this pharmaceutical composition also has the effect of enhancing immunity.This preparation of pharmaceutical compositions method process stabilizing that we provide, favorable reproducibility.Established quality standard by modern analysis means and fingerprint pattern technology, and quality controllable, and good stability can further be developed as newtype drug.
Further specify the present invention with specific embodiment below, but can not be used for unique qualification the present invention.
Specific embodiment:
Embodiment 1: the preparation of pharmaceutical composition of viola yedoensis
Getting the 500g Herba Violae decocts with water twice, each 5000ml decocted two hours, merge extracted twice liquid and be concentrated into relative density 1.20-1.25 (50 ℃), fully stir the ethanol standing over night that adds equivalent down, collecting precipitation, precipitation is removed the ester soluble components with macroporous adsorbent resin (ADS-7 macroporous adsorbent resin) in the dissolving back again, effluent and 1 times of bed volume water elution liquid merge, with the ultrafilter membrane ultrafiltration of the molecular weight 5000 that dams, ultrafiltrate be concentrated into most dry pharmaceutical composition of viola yedoensis.
Sample number into spectrum: ZT-1
Embodiment 2: the preparation of pharmaceutical composition of viola yedoensis
Getting the 500g Herba Violae decocts with water twice, each 5000ml decocted two hours, merge extracted twice liquid and be concentrated into relative density 1.20-1.25 (50 ℃), fully stir the ethanol standing over night that adds equivalent down, collecting precipitation, precipitation dissolving back cold preservation is again spent the night, filter, subsequent filtrate is crossed 50,000 ultrafiltration post ultrafiltration, ultrafiltrate is removed the ester soluble components with macroporous adsorbent resin (ADS-7 macroporous adsorbent resin), effluent and 1 times of bed volume water elution liquid merge, with the ultrafiltration post ultrafiltration of the molecular weight 5000 that dams, ultrafiltrate be concentrated into most dry pharmaceutical composition of viola yedoensis;
Sample number into spectrum: ZT-2
Embodiment 3: the preparation of pharmaceutical composition of viola yedoensis
Getting the 500g Herba Violae decocts with water twice, each 5000ml decocted two hours, merge extracted twice liquid and be concentrated into relative density 1.20-1.25 (50 ℃), fully stir the ethanol standing over night that adds equivalent down, collecting precipitation, precipitation dissolving back cold preservation is again spent the night, filter, after subsequent filtrate concentrates again precipitate with ethanol once, precipitation is with the after-filtration that spends the night of cold preservation behind the water dissolution, subsequent filtrate is crossed 50,000 ultrafiltration post ultrafiltration, ultrafiltrate is removed the ester soluble components with macroporous adsorbent resin (ADS-7 macroporous adsorbent resin), effluent and 1 times of bed volume water elution liquid merge, with the ultrafiltration post ultrafiltration of the molecular weight 3000 that dams, ultrafiltrate be concentrated into most dry pharmaceutical composition of viola yedoensis;
Sample number into spectrum: ZT-3
Embodiment 4: the preparation of injection Herba Violae lyophilized powder
Get pharmaceutical composition of viola yedoensis 4g, add 250ml water for injection and fully dissolve, the cold preservation after-filtration that spends the night, subsequent filtrate adds the mannitol of 32g, fully add water for injection to 400ml after the dissolving, regulate pH value to 6-7, add and cross 0.22 micron microporous filter membrane after active carbon removes thermal source, be sub-packed in the 7ml cillin bottle, every 4ml, jump a queue, lyophilizing, gland is promptly.Sample number into spectrum: HQDD-1
Embodiment 5: the preparation of injection Herba Violae lyophilized powder
Get pharmaceutical composition of viola yedoensis 2g, add 250ml water for injection and fully dissolve, the cold preservation after-filtration that spends the night, subsequent filtrate adds the mannitol of 32g, fully add water for injection to 400ml after the dissolving, regulate pH value to 6-7, add and cross 0.22 micron microporous filter membrane after active carbon removes thermal source, be sub-packed in the 7ml cillin bottle, every 4ml, jump a queue, lyophilizing, gland is promptly.Sample number into spectrum: HQDD-2
Embodiment 6: the preparation of injection Herba Violae lyophilized powder
Get pharmaceutical composition of viola yedoensis 4g, add 250ml water for injection and fully dissolve, the cold preservation after-filtration that spends the night, subsequent filtrate adds the mannitol of 24g, fully add water for injection to 400ml after the dissolving, regulate pH value to 6-7, add and cross 0.22 micron microporous filter membrane after active carbon removes thermal source, be sub-packed in the 7ml cillin bottle, every 4ml, jump a queue, lyophilizing, gland is promptly.Sample number into spectrum: HQDD-3
Embodiment 7: the viola yedoensis preparation of soft capsule
Get pharmaceutical composition of viola yedoensis 4g, add soybean oil, Cera Flava, mixing is made 100 of soft capsules, promptly.Sample number into spectrum: ZHR-1.
Embodiment 8: the preparation of Herba Violae sheet
Pharmaceutical composition of viola yedoensis 4g adds an amount of microcrystalline Cellulose, crospolyvinylpyrrolidone, pulverize, an amount of ethanol is softening, granulates 50 ℃ of dryings behind 60 mesh sieves excessively, cross 60 mesh sieve granulate, add an amount of carboxymethyl starch sodium, Aspartane, magnesium stearate uniform mixing, be pressed into 100, promptly.
Embodiment 9: the Herba Violae total polysaccharides is to the influence of mice non-specific immunity
Experiment medicine: Herba Violae total polysaccharides, normal saline, lentinan.
Laboratory animal: female Sexual health Balb/c mice, body weight 18～22g
Experimental technique: get 50 of female healthy mices, be divided into 5 groups at random, normal saline blank group, low dosage viola yedoensis group, middle dosage viola yedoensis group, high dose viola yedoensis group, 10 every group of lentinan matched groups.Respectively organize medicine for respectively mouse mainline, inject 7d continuously.Put to death mice on the 8th day and weigh, dissect, get spleen, thymus is accurately weighed.Result organ index (mg/10g)=thymus or spleen weight (mg)/mice body weight * 10g.The results are shown in Table 1:
Table 1 Herba Violae total polysaccharides is to the mouse immune organ, spleen index, the influence of thymus index
| Group | Dosage (mg/kg) | Spleen index (mg/10g) | Thymus index (mg/10g) |
| The normal saline blank is to dosage Herba Violae total polysaccharides high dose Herba Violae total polysaccharides lentinan in the group low dosage Herba Violae total polysaccharides | - 5 10 15 10 | 74.25±16.48 79.44±14.58 90.45±16.89 119.47±22.51 ** 110.56±22.62 ** | 18.55±8.01 21.02±7.95 24.65±9.05 28.53±10.41 ** 27.26±10.53 ** |
Annotate: contrast with the blank group
*P＜0.01
Embodiment 10: the different molecular weight viola yedoensis is external to be influenced the mouse boosting cell breeder reaction
Experiment medicine: low-molecular-weight viola yedoensis (＜5,000 molecular weight), intermediate molecular weight viola yedoensis (5,000-20,000), high molecular viola yedoensis (＞20,000 molecular weight), canavaline (ConA), normal saline.
Laboratory animal: female Sexual health Balb/c mice, body weight 18～22g.
Experimental technique: after taking off neck execution mice, the aseptic mouse spleen of getting adds Hank ' s liquid and grinds, and filters in (200 order), and washing is suspended in the 10%NBS-RPIM-1640 nutritional solution, and being mixed with cell concentration is (1 * 1010L-1) splenocyte suspension.In 96 well culture plates, every hole adds 100 μ l splenocyte suspensions.Experiment is divided into 9 groups, every group 10 hole.1 group: blank group (10%NBS-RPIM-1640 nutritional solution, 100 μ l).2 groups: viola yedoensis (low-molecular-weight) 100mg/L, 100 μ l.3 groups: viola yedoensis (middle molecular weight) 100mg/L, 100 μ l.4 groups: viola yedoensis (high molecular) 100mg/L, 100 μ l.5 groups: ConA (5mgL-1) induces splenocyte propagation matched group (50 μ lConA+50 μ l 10%NBS-RPIM-1640 nutritional solution).Add respectively and respectively organize medicinal liquid in culture plate, put 37 ℃, saturated humidity is cultivated 48h under the condition of 5%CO2,6h before stopping, and every hole adds [3H]-TdR 20 μ l (7.4Bq/ hole).After cultivating end, with the bull cell harvestor with cell harvesting on 49 type glass fiber filter paper, 80 ℃ of oven dry, put and add scintillation solution 1ml (xylene solution of 0.5%PPO and 0.05%POPOP) in the scintillating disc, read value on the BeckmanL5-6500 type liquid scintillation counter, with reaction splenocyte propagation degree as [3H]-TdR dpm.The results are shown in Table 2.
Table 2 different molecular weight viola yedoensis is external to be influenced the mouse boosting cell breeder reaction
| Group | Dosage (mgL -1) | [ 3H]-TdR uptake(dpm) |
| 1 group (blank group) 2 groups of 3 groups of viola yedoensis of viola yedoensis (low) (in) 4 groups of 5 groups of viola yedoensis (height) (ConA) | - 100 100 100 5 | 464.0±41.0 808.0±48.0 ** 1574.0±38.0 ** 957.0±34.0 ** 1042.0±55.0 |
Annotate: with 1 group of blank group contrast
*P＜0.01
With 5 groups (ConA) contrast △ △ P＜0.01
Embodiment 11: the different molecular weight viola yedoensis is to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic function
Experiment medicine: low-molecular-weight viola yedoensis (＜5,000 molecular weight), intermediate molecular weight
Viola yedoensis (5,000-20,000), high molecular viola yedoensis (＞20,000 molecular weight).
Laboratory animal: female Sexual health Balb/c mice, body weight 18～22g.
Experimental technique: get 50 female Sexual health Balb/c mices, be divided into 5 groups at random, normal saline blank group, low-molecular-weight viola yedoensis group, intermediate molecular weight viola yedoensis group, high molecular viola yedoensis group, 10 every group.Respectively organize medicine for respectively mouse mainline, inject 7d continuously.Took off neck on the 8th day and put to death mice, cut off abdominal cavity skin rapidly, aseptic injection Hank ' s solution 3ml gently rubs abdominal part in the abdominal cavity, extracts peritoneal fluid, and the centrifugal 10min of 1000r/min gets supernatant.Be settled to 5ml with the PH7.4 phosphate buffer, add 0.5% chicken red blood cell 0.4m1, in 37 ℃, 5%CO2 supports case hatches 30min.Get an amount of centrifugal push jack, with Rui Shi liquid dyeing 1 minute, add the equivalent distilled water again, mix gently, after 5 minutes, use distilled water flushing, wait to do, oily mirror is observed microscopy down, calculates and engulfs percent=(engulfing the macrophage number of macrophage number/counting of CRBC) * 100% and phagocytic index=(the macrophage number of CRBC number/counting of being engulfed).The results are shown in Table 5.
Table 5 different molecular weight viola yedoensis is to the influence of macrophage phagocytosis of mice
| Group | Dosage (mg/kg) | Phagocytic rate (%) | Phagocytic index |
| Blank group viola yedoensis (low) viola yedoensis (in) viola yedoensis (height) | - 10 10 10 | 39.3±4.7 47.5±5.6 * 72.3±8.9 ** 58.4±7.6 ** | 0.51±0.13 0.76±0.11 * 1.10±0.15 ** 0.84±0.13 ** |
Annotate: contrast with the blank group
*P＜0.05,
*P＜0.01
Claims (18)
1, a kind of pharmaceutical composition of viola yedoensis is made through extracting purification by Herba Violae, and wherein polysaccharide component accounts for more than 50% of solid content.
2, as claim 1 described pharmaceutical composition of viola yedoensis, it is characterized in that polysaccharide component is not less than 80%.
3, as claim 1 or 2 described pharmaceutical composition of viola yedoensis, it is characterized in that mean molecule quantity is between 11000 ± 2000, wherein the polysaccharide component of molecular weight 5000-20000 is not less than 80%.
4, as claim 3 described viola yedoensis, it is characterized in that said composition has a topmost polysaccharide chromatographic peak in the GPC gel chromatography, mean molecule quantity is between 11000 ± 2000.
5, as claim 4 described pharmaceutical composition of viola yedoensis, it is characterized in that polyoses content reaches more than 90%.
6, a kind of chromatographically pure viola yedoensis, this polysaccharide mean molecule quantity of GPC chromatographic determination is between 11000 ± 2000, and the polysaccharide component of 5000-20000 is not less than 80%, molecular weight distribution 1.10-1.20, Mz/Mw 1.20-1.30.
7, a kind of preparation method of pharmaceutical composition of viola yedoensis may further comprise the steps:
1) the Herba Violae medical material obtains crude polysaccharides with the mode of conventional water extraction reuse ethanol precipitation, and perhaps elder generation obtains crude polysaccharides with the mode of organic solvent degreasing reuse water extraction;
2) aqueous solution of crude polysaccharides is crossed the ultrafiltration post of the molecular weight 20,000-200,000 that dams, and collects ultrafiltrate;
3) ultrafiltrate is collected the ultrafiltration mother solution after the ultrafiltration post of molecular weight less than 5000 that dam;
4) the ultrafiltration mother solution of the 3rd step collection concentrates after drying and promptly gets pharmaceutical composition of viola yedoensis.
8,, it is characterized in that for the first time 50,000 or 100,000 ultrafiltration post is used in ultrafiltration as the preparation method of claim 7 described pharmaceutical composition of viola yedoensis.
9,, it is characterized in that the ultrafiltration post of the use of ultrafiltration for the second time 5000 or 3000 as the preparation method of claim 8 described viola yedoensis.
10,, it is characterized in that ultrafiltrate is crossed macroporous adsorbent resin after the ultrafiltration first time as the preparation method of claim 7 described pharmaceutical composition of viola yedoensis.
11,, it is characterized in that resin comprises D101, D380, D280, ADS-7, ADS-8, HPD-300 or SA-1 model as the preparation method of claim 10 described pharmaceutical composition of viola yedoensis.
12,, it is characterized in that resin is strong polar macroporous adsorption resin as the preparation method of claim 10 described pharmaceutical composition of viola yedoensis.
13,, it is characterized in that resin is ADS-7 or SA-1 resin as the preparation method of claim 12 described pharmaceutical composition of viola yedoensis.
14,, it is characterized in that performing step is as the preparation method of claim 13 described pharmaceutical composition of viola yedoensis:
1) the Herba Violae medical material obtains crude polysaccharides with the mode of conventional water extraction reuse ethanol precipitation, and perhaps elder generation obtains crude polysaccharides with the mode of organic solvent degreasing reuse water extraction;
2) crude polysaccharides solution is crossed 50,000 ultrafiltration post, collects ultrafiltrate;
3) ultrafiltrate is crossed the SA-1 resin, collects effluent and water lotion and merges;
4) the 3rd step gained solution is crossed 5000 ultrafiltration post, gets the ultrafiltration mother solution;
5) the ultrafiltration mother solution dry pharmaceutical composition of viola yedoensis.
15,, it is characterized in that performing step is as the preparation method of claim 13 described pharmaceutical composition of viola yedoensis:
1) the Herba Violae medical material obtains crude polysaccharides with the mode of conventional water extraction reuse ethanol precipitation, and perhaps elder generation obtains crude polysaccharides with the mode of organic solvent degreasing reuse water extraction;
2) crude polysaccharides solution is crossed 50,000 ultrafiltration post, collects ultrafiltrate;
3) ultrafiltrate is crossed the ADS-7 resin, collects effluent and water lotion and merges;
4) the 3rd step gained solution is crossed 5000 ultrafiltration post, gets the ultrafiltration mother solution;
5) the ultrafiltration mother solution dry pharmaceutical composition of viola yedoensis.
16, as the application of any pharmaceutical composition of viola yedoensis of claim 1-6 in preparation anti-virus aspect medicine, comprise hepatitis B virus or HIV (human immunodeficiency virus).
17, as the application of any pharmaceutical composition of viola yedoensis of claim 1-6 in preparation enhance immunity medicine.
18, as the application of any pharmaceutical composition of viola yedoensis of claim 1-6 in preparation used as adjuvant drug for antitumor thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610035666 CN1883619A (en) | 2006-05-29 | 2006-05-29 | Pharmaceutical composition of viola yedoensis and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610035666 CN1883619A (en) | 2006-05-29 | 2006-05-29 | Pharmaceutical composition of viola yedoensis and method for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1883619A true CN1883619A (en) | 2006-12-27 |
Family
ID=37582002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610035666 Pending CN1883619A (en) | 2006-05-29 | 2006-05-29 | Pharmaceutical composition of viola yedoensis and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1883619A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104041728A (en) * | 2014-06-16 | 2014-09-17 | 孙锐 | Preparing method for boji red fig polysaccharide jellies |
| CN109010524A (en) * | 2018-09-29 | 2018-12-18 | 宁夏医科大学 | Application of the n-butanol portion of viola mandshurica ethanol extract as epidemic prevention liver injury medicament |
| CN111471119A (en) * | 2020-05-30 | 2020-07-31 | 宁夏厚泽生物医药科技有限公司 | Plant polysaccharide and application thereof in preparation of cosmetics for removing freckles and whitening |
-
2006
- 2006-05-29 CN CN 200610035666 patent/CN1883619A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104041728A (en) * | 2014-06-16 | 2014-09-17 | 孙锐 | Preparing method for boji red fig polysaccharide jellies |
| CN109010524A (en) * | 2018-09-29 | 2018-12-18 | 宁夏医科大学 | Application of the n-butanol portion of viola mandshurica ethanol extract as epidemic prevention liver injury medicament |
| CN111471119A (en) * | 2020-05-30 | 2020-07-31 | 宁夏厚泽生物医药科技有限公司 | Plant polysaccharide and application thereof in preparation of cosmetics for removing freckles and whitening |
| CN111471119B (en) * | 2020-05-30 | 2022-02-01 | 广西下班乐生物科技有限公司 | Plant polysaccharide and application thereof in preparation of cosmetics for removing freckles and whitening |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1194702C (en) | Herba-Epimedii extract for treating prostatic hyerplasia and use in preparing medicine | |
| CN1883619A (en) | Pharmaceutical composition of viola yedoensis and method for preparing same | |
| CN1108310C (en) | Algae polysaccharide and its preparation and use | |
| CN1931190A (en) | Toad skin extract and its medicine prepn and their prepn | |
| CN100349579C (en) | Composition of ginseng-astragalus polysaccharides and its preparing method | |
| CN1903213A (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN1973853A (en) | Hemostatic and analgetic medicine composition and its prepn process | |
| CN1123577C (en) | Ocean thalassiomycete hypoxylon polyose and its extracting process and application | |
| CN1872101A (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, distilling method and application | |
| CN100339090C (en) | Novel pomegranate leaf extract and medicinal use thereof | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN100343266C (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method | |
| CN1817351A (en) | Production of variolaria amra medicinal extract and its medicinal preparation | |
| CN1733042A (en) | Isatis root extract and its preparation method | |
| CN1712052A (en) | Medicinal preparation for treating hepatitis its production and quality control | |
| CN1846695A (en) | Application of 3,5,7,3',4',5'-hexahydroxyl-2,3-dihydroflavone in preparing medicine | |
| CN1273114C (en) | Sichuan aconite root freeze-dried powder injection and its preparing method | |
| CN1515277A (en) | Method for extractings ubstance resisting respiratory syncytial virus from patrinia | |
| CN1254260C (en) | Medicine composition containing epimedium extract | |
| CN1686378A (en) | Compound houttuynia injection, its preparation method and application | |
| CN1278698C (en) | Freeze dried injection of seeding of autumnal sowthistle-leaf ixeris and preparation method thereof | |
| CN1283650C (en) | Process of extracting total flavone glycoside from mistletoe and medicine composition thereof | |
| CN101036684A (en) | Isatis-Root extractive and the purifying method and the medicine combination | |
| CN100344309C (en) | Refining method for Liuweidihuang compound preparation by membrane technology separation | |
| CN1872155A (en) | Microspheres in use for injection of astragalus root and red sage root, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |